semaglutide ckd without diabetes Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Effects of Once-Weekly Semaglutide #Nephpearls #Cardiorenal FLOW https://pubmed.ncbi.nlm.nih.gov/38785209/ SUSTAIN 6 https://pubmed.ncbi.nlm.nih.gov/27633186/ SUSTAIN 6 Posthoc https://pubmed.ncbi.nlm.nih.gov/39081763/

29.84

★★★★☆4.8 (126)

Semaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights

29.23

★★★★★4.9 (98)

Get With the FLOW! in: Kidney News Volume 16 Issue 8 (2024)

28.43

★★★★★5.0 (157)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

26.33

★★★★★4.7 (84)

In participants with type 2 #diabetes and #kidney disease, consistent benefits of semaglutide (#ozempic) on major kidney outcomes, major #heart outcomes, and all-cause death were observed regardless of baseline mineralocorticoid antagonist use (

27.27

★★★★★4.9 (203)

❇️Patients with obesity, type 2 #diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. This study, the FLOW trial now published, evaluated treatment with semaglutide (#

22.12

★★★★★5.0 (176)

Semaglutide lowers UACR in overweight CKD patients

23.78

★★★★★4.8 (132)